Marketing

  • David Ricks, CEO of Eli Lilly, speaks alongside U.S. President Donald Trump, administration officials and fellow pharmaceutical executives on November 06, 2025 in Washington, DC.
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill

    Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's currently speeding along “at pace.” 

    By • Jan. 14, 2026
  • Plant, sustainability and environment with hands of business people.
    Image attribution tooltip

    ShutterStock/PeopleImages

    Image attribution tooltip
    Sponsored by Cryopak Inc.

    Building more sustainable cold chain packaging through innovation

    Working towards the future of cold chain packaging: sustainable packaging without performance tradeoffs.

    By Cryopak • Jan. 12, 2026
  • A stylized illustration of a pill breaking apart into smaller pills. Explore the Trendline➔
    Image attribution tooltip
    Brian Tucker / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Trendline

    Commercialization

    New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.

    By BioPharma Dive staff
  • Close-up on a scientist using a mobile app on a digital tablet while working at the laboratory
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Argenx falters in effort to expand immune drug’s use

    The company will stop two trials testing its blockbuster therapy Vyvgart in thyroid eye disease after treatment was judged to be ineffective at an interim checkpoint.

    By • Dec. 15, 2025
  • Cassidy speaks in front of poster board during a Senate Finance Committee hearing.
    Image attribution tooltip
    Rebecca Pifer/BioPharma Dive
    Image attribution tooltip

    Crapo, Cassidy propose enhanced ACA subsidy alternative

    The legislation, which is scheduled for a vote Thursday, would send funds directly to health savings accounts paired with bronze or catastrophic plans offered on the Affordable Care Act exchanges.

    By Emily Olsen • Dec. 11, 2025
  • A micrograph of a myeloma neoplasm in a bone marrow biopsy.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    J&J’s ‘remarkable’ Tecvayli data support earlier use in multiple myeloma

    In a step forward for bispecific antibodies, study results presented at ASH suggest a Tecvayli-based combination could have curative potential early in a patient’s disease course.

    By • Dec. 9, 2025
  • A sign with Eli Lilly's logo sits outside of the company's headquarters on March 17, 2024 in Indianapolis.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    At ASH, Lilly makes case to widen Jaypirca use in leukemia, lymphoma

    In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety advantages that could make it a preferred treatment in early lines of care. 

    By • Dec. 7, 2025
  • A photo of several members sitting side by side with a blue CDC background and screen that says U.S. Centers for Disease Control and Prevention Advisory Committee on Immunization Practices
    Image attribution tooltip
    Elijah Nouvelage via Getty Images
    Image attribution tooltip
    Vaccines

    RFK Jr.’s hand-picked panel questions childhood vaccine schedule

    After weakening an endorsement for the hepatitis B vaccine, ACIP began debating the merits of the protocol used to inoculate U.S. children against many infectious diseases.

    By • Dec. 5, 2025
  • blood cells lab
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Hemophilia gene therapies are struggling on the market, even as innovation soars

    The business case for hemophilia gene therapy still isn’t adding up due to persistent market barriers.

    By Kelly Bilodeau • Dec. 5, 2025
  • Two prescription drug cartons stand side by side on a counter, each bearing the word Wegovy.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    CMS sets 2027 Medicare prices for Wegovy, Trelegy and 13 other drugs

    The second round of negotiations cuts spending an aggregate 44% over 2024 list prices as the federal government extends restraints over more medicines.

    By • Nov. 26, 2025
  • Location of Delaware Court of Chancery in Wilmington
    Image attribution tooltip
    Mark Makela via Getty Images
    Image attribution tooltip

    GSK, Anaptysbio sue each other over Jemperli revenue

    As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding development of the cancer immunotherapy.

    By • Nov. 21, 2025
  • FDA
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    With new approvals, Regeneron’s higher-dose Eylea gets more competitive

    Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.

    By Kristin Jensen • Nov. 20, 2025
  • Image attribution tooltip
    Jonathan Gardner/BioPharma Dive
    Image attribution tooltip

    Agios shares fall on mixed sickle cell results for blood disease drug

    Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its commercial outlook and the company’s reinvention as a rare disease specialist.

    By • Nov. 19, 2025
  • David Ricks, CEO of Eli Lilly, speaks alongside U.S. President Donald Trump, administration officials and fellow pharmaceutical executives on November 06, 2025 in Washington, DC.
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip
    Trump administration

    Novo, Lilly cut deal with Trump to lower prices of obesity drugs

    The agreement will make Wegovy and Zepbound available to some Medicare enrollees for $245 per month, and starter doses of pill versions, once approved, for $149 monthly.

    By • Updated Nov. 7, 2025
  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Vertex’s new pain, blood disorder drugs miss Wall Street expectations

    While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear revenue misses,” wrote a Raymond James analyst.

    By • Nov. 4, 2025
  • women using health app on phone
    Image attribution tooltip
    Permission granted by Aptar Digital Health
    Image attribution tooltip
    Sponsored by Aptar Digital Health

    4 must-have capabilities in a digital health partner in the era of AI

    Unlock the 4 must-have traits that make digital health partners game-changers in pharma.

    Nov. 3, 2025
  • man in a dark blue suit speaks in the oval office
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    FDA, aiming to lower drug costs, moves to speed approval of biosimilars

    The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help developers bring them to market more quickly and cheaply. 

    By • Oct. 29, 2025
  • Glucagon-like peptide 1 (GLP1, 7-36) molecule The glucagon like peptide-1 receptor has a strong effect on the management of type 2 diabetes mellitus.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly aligns with Walmart in bid to broaden access to discounted Zepbound

    The deal, which enables patients to pick up orders placed through Lilly’s online channel at Walmart pharmacies, is the latest move by the company to expand its direct-to-consumer services. 

    By • Oct. 29, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Iambic partners with Jazz; Merck breaks ground on $3B plant

    The biotechs will assess a combination of two drugs against HER2-positive breast cancer. Elsewhere, Merck unveiled the latest piece of its more than $70 billion domestic manufacturing investment.

    By BioPharma Dive staff • Oct. 21, 2025
  • Close-up view of the Novo Nordisk logo mounted on the exterior wall of a building. The logo features a stylized blue Apis bull with a sun disk above its head, symbolizing the company's identity. The background shows a tan brick wall and part of a leafless tree in the foreground under a clear blue sky."
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Novo’s main shareholder pushes out more than half of company’s board

    The Novo Foundation chair said the current board of the Wegovy maker, which is already dealing with layoffs and a CEO change, was too slow to react to obesity market shifts.

    By • Oct. 21, 2025
  • Mark Cuban at HLTH
    Image attribution tooltip
    Susanna Vogel/BioPharma Dive
    Image attribution tooltip

    Mark Cuban says Cost Plus Drugs will partner with TrumpRx

    Cost Plus Drugs is sharing pricing data with TrumpRx, the administration’s new direct-to-consumer prescription drug website set to launch next year.

    By Susanna Vogel • Oct. 20, 2025
  • A micrograph of a myeloma neoplasm in a bone marrow biopsy.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    J&J claims success in study testing earlier Tecvayli use in multiple myeloma

    The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to later-line settings for the persistent blood cancer.

    By • Oct. 16, 2025
  • Side view portrait of doctor and patient talking in a clinic setting.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Deep Dive

    AI could transform healthcare. Can safety-net providers keep up?

    Implementing artificial intelligence requires significant human labor and technical expertise, threatening to create a digital divide between highly resourced health systems and safety-net providers.

    By Emily Olsen • Oct. 3, 2025
  • The exterior of Amgen's office building in South San Francisco, with a sculpted company sign in the foreground and leafless trees on a grassy lawn.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Amgen claims ‘landmark’ study result that could widen heart drug’s use

    In a first-of-its-kind finding, Amgen’s PCSK9 drug protected heart health when tested as a “primary prevention” therapy, which could pave the way for access to a much broader population. 

    By • Oct. 2, 2025
  • U.S. President Donald Trump shakes hands with President of the European Commission Ursula von der Leyen as he announces a trade deal with the EU at Trump Turnberry golf club on July 27, 2025 .
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Pharma reshoring

    Key exemptions could limit impact of Trump’s pharmaceutical tariffs

    Carve-outs for generics, European exports and companies onshoring drug production will likely shield most branded drugs from the 100% levies Trump announced Thursday.

    By • Sept. 26, 2025
  • A child receives a standard immunization at Dr. Gary Kramer's pediatric office on September 15, 2025, in Coral Gables, Florida.
    Image attribution tooltip
    Joe Raedle / Staff via Getty Images
    Image attribution tooltip
    Deep Dive

    Disparity in vaccine access between states roils patients, providers

    Recent changes to federal guidance on COVID vaccinations have providers worried about what’s to come. “We have opened a door to not using science to guide care,” one physician said.

    By Susanna Vogel • Sept. 23, 2025